ArriVent BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	27.19	24.18	15.3	9.71	6.47
Research & Development	129.68	153.35	79	64.88	30.43
Total Operating Expenses	156.87	177.53	94.31	74.59	36.91
Operating Income	-156.87	-177.53	-94.31	-74.59	-36.91
Interest Income	11.63	11.23	13.82	5.26	-
Total Non-Operating Income (Expense)	11.63	11.23	13.82	5.26	-
Pretax Income	-145.24	-166.31	-80.49	-69.33	-36.91
Net Income	-145.24	-166.31	-80.49	-69.33	-36.91
Net Income to Common	-145.24	-166.31	-80.49	-69.33	-36.91
Shares Outstanding (Basic)	41	38	31	2	1
Shares Outstanding (Diluted)	41	38	31	2	1
Shares Change (YoY)	22.44%	22.22%	1369.88%	67.64%	-
EPS (Basic)	-3.47	-4.32	-2.56	-32.38	-28.90
EPS (Diluted)	-3.47	-4.32	-2.56	-32.38	-28.90
Free Cash Flow	-134.47	-160.59	-70.21	-55.84	-43.63
Free Cash Flow Per Share	-3.26	-4.18	-2.23	-26.08	-34.16
EBITDA	-156.87	-177.53	-94.31	-74.59	-36.91
EBIT	-156.87	-177.53	-94.31	-74.59	-36.91

SEC Filings: 10-K · 10-Q